These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7937538)

  • 1. A regulatory and industrial perspective of the use of carbon-14 and tritium isotopes in human ADME studies.
    Dain JG; Collins JM; Robinson WT
    Pharm Res; 1994 Jun; 11(6):925-8. PubMed ID: 7937538
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarker Development Strategies - surmounting scientific and regulatory barriers in bringing innovative medicine to market.
    Shi M
    IDrugs; 2007 Apr; 10(4):246-8. PubMed ID: 17390245
    [No Abstract]   [Full Text] [Related]  

  • 3. Off-label promotion.
    Somberg J
    Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharma allowed to make own genetics.
    Owens J
    Nat Rev Drug Discov; 2005 Jul; 4(7):530. PubMed ID: 16075483
    [No Abstract]   [Full Text] [Related]  

  • 5. Controversy. IV: Population pharmacokinetics, NONMEM and the pharmacokinetic screen; academic, industrial and regulatory perspectives.
    Colburn WA
    J Clin Pharmacol; 1989 Jan; 29(1):1-6. PubMed ID: 2708544
    [No Abstract]   [Full Text] [Related]  

  • 6. Industry perspective on the proposed changes to the GMPs.
    Dana RL; Mehringer N
    PDA J Pharm Sci Technol; 1997; 51(4):163-5. PubMed ID: 9277126
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory evaluation of biotechnology drugs: current trends in the United States.
    Sobel S
    Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148
    [No Abstract]   [Full Text] [Related]  

  • 8. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA's critical path initiative: a brief introduction.
    Coons SJ
    Clin Ther; 2009 Nov; 31(11):2572-3. PubMed ID: 20110002
    [No Abstract]   [Full Text] [Related]  

  • 10. Are the drug-regulatory agencies paper villains?
    Smith T
    Br Med J; 1980 Nov; 281(6251):1333-5. PubMed ID: 7002251
    [No Abstract]   [Full Text] [Related]  

  • 11. Generic Pharmaceutical Association (GPhA) - 2008 annual meeting.
    Kuhrt K
    IDrugs; 2008 Apr; 11(4):267-70. PubMed ID: 18379960
    [No Abstract]   [Full Text] [Related]  

  • 12. The learned intermediary doctrine: past, present and future.
    Alsobrook HB
    Leg Med; 1994; ():269-80. PubMed ID: 7830482
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congress, the FDA, and the fair development of new medications for children.
    McKinney RE
    Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA mulls over paperless labeling.
    Young D
    Am J Health Syst Pharm; 2007 Jun; 64(11):1120, 1122. PubMed ID: 17519446
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 17. Addressing Pharmaceutical Injuries: The US Landscape.
    Bakker C; Honig N
    Clin Pharmacol Ther; 2018 Mar; 103(3):384-385. PubMed ID: 28850676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RECENT DRUG LEGISLATION IN THE UNITED STATES.
    AESCHLIMANN J
    Pharm Acta Helv; 1964; 39():193-6. PubMed ID: 14246809
    [No Abstract]   [Full Text] [Related]  

  • 19. A survey of developments in food and drug law from July 1998 to November 1999.
    Littlefield N; Hada NR
    Food Drug Law J; 2000; 55(1):35-56. PubMed ID: 12296348
    [No Abstract]   [Full Text] [Related]  

  • 20. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.